Delivery Order SPE2DB24D2106-SPE2DB26FATXU
- Not listed
- The Defense Logistics Agency awarded a $5,502.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 100 units of Atovaquone-Proguanil 250-100, an antimalarial medication used for malaria prophylaxis and treatment. The award, issued on October 17, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, indicating DMS Pharmaceutical Group competed...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,084.55 to DMS Pharmaceutical Group Inc. for 100 units of Atovaquone-Proguanil 250-100, an antimalarial medication. The award, issued on September 19, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $2,067.00 and has a completion date of June 26, 2024. DMS Pharmaceutical Group will supply the DLA with 4564993076 units of Atovaquone-Proguanil 250-100mg tablets. This delivery order is issued under a larger indefinite delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 29, 2025, for the supply of Atovaquone-Proguanil 250-100 tablets (100 count). This firm fixed-price delivery order, valued at $1,667.64, represents a single-line item procurement with a completion deadline of July 30, 2025. The award carries no set-aside designation, allowing the vendor to compete in...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of Atovaquone-Proguanil 250-100mg tablets. The contract has a completion date of February 14, 2024 and a potential value of $1,929.20. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDV) 4600082013 with the Defense Logistics Agency, valued at up to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a firm fixed-price delivery order valued at $4,883.30 for atovaquone and proguanil pharmaceutical products. The contract was awarded on September 29, 2025, with an ultimate completion date of October 9, 2025, by the Defense Logistics Agency's Medical Supply Chain division. This delivery order carries no set-aside designation and represents a specific pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,640.08 firm fixed-price delivery order is for the supply of Atovaquone-Proguanil 250-100 100s, a pharmaceutical product. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,250.73 contract is for the delivery of 4,567,951,594 units of Atovaquone-Proguanil 250-100 100s, a prescription medication. The contract has an ultimate completion date of April 18, 2025 and was awarded on April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite...
- This is a Delivery Order issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $11,332.80 Firm Fixed Price contract is for the delivery of Atovaquone 250mg/Proguanil HCl 100mg tablets, with a period of performance through June 25, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) valued up to $499,999,999 that DMS...
- The U.S. government's Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $1,390.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of ATOVAQUONE/PROGUANIL, a pharmaceutical product, and does not have a set-aside designation. This delivery order contract is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FATXUDelivery Order
The Defense Logistics Agency awarded a $1,727.47 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Atovaquone-Proguanil 250-100mg tablets (100 count). The delivery order, issued on October 22, 2025, with an ultimate completion date of October 23, 2025, carries no set-aside designation and will be performed in Conshohocken, Pennsylvania. This award represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's broader engagement with the Defense Logistics Agency's Medical Supply Chain division. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The PPV-G GEN V program is part of the broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical and medical consumable supply to Department of Defense healthcare facilities worldwide, positioning DMS Pharmaceutical Group as a critical regional supplier for military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 10/22/25 |